BPMC · Insider Trading
Blueprint Medicines Corporation
Every open-market purchase and sale reported by BPMC officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-07-21 | Percy H. Carter | Chief Scientific Officer | MIXED | −53,155 | — |
| 2025-07-21 | Alexis Borisy | Director | MIXED | −78,062 | — |
| 2025-07-21 | L. Becker Hewes | Chief Medical Officer | MIXED | −30,419 | — |
| 2025-07-21 | Habib J Dable | Director | MIXED | −12,644 | — |
| 2025-07-21 | Philina Lee | Chief Commercial Officer | MIXED | −41,996 | — |
| 2025-07-21 | Jeffrey W. Albers | Director | MIXED | −150,532 | — |
| 2025-07-21 | Tracey L McCain | EVP & Chief Legal Officer | MIXED | −66,842 | — |
| 2025-07-21 | John Tsai | Director | MIXED | −12,644 | — |
| 2025-07-21 | Ariel Hurley | Principal Accounting Officer | MIXED | −17,064 | — |
| 2025-07-21 | Kate Haviland | Chief Executive Officer | MIXED | −165,929 | — |
| 2025-07-21 | Fouad Namouni | PRESIDENT, R & D | MIXED | −75,781 | — |
| 2025-07-21 | Daniella Beckman | Director | MIXED | −14,744 | — |
| 2025-07-21 | Michael Landsittel | Chief Financial Officer | MIXED | −72,924 | — |
| 2025-07-21 | Lonnel Coats | Director | D | −6,144 | — |
| 2025-07-21 | Debra Durso-Bumpus | Chief People Officer | MIXED | −49,606 | — |
| 2025-07-21 | Lynn Seely | Director | MIXED | −17,156 | — |
| 2025-07-21 | Mark Alan Goldberg | Director | MIXED | −22,156 | — |
| 2025-07-21 | Christina Rossi | Chief Operating Officer | MIXED | −63,546 | — |
| 2025-07-08 | Christina Rossi | CHIEF OPERATING OFFICER | Sell | −1,172 | −$150.31K |
| 2025-07-08 | Percy H. Carter | CHIEF SCIENTIFIC OFFICER | Sell | −1,051 | −$134.79K |
| 2025-06-24 | Jeffrey W. Albers | Director | A | +3,902 | +$499.92K |
| 2025-06-24 | Mark Alan Goldberg | Director | A | +3,902 | +$499.92K |
| 2025-06-24 | Alexis Borisy | Director | A | +3,902 | +$499.92K |
| 2025-06-24 | Lonnel Coats | Director | A | +3,902 | +$49.99M |
| 2025-06-24 | Lynn Seely | Director | A | +3,902 | +$499.92K |
| 2025-06-24 | Habib J Dable | Director | A | +3,902 | +$499.92K |
| 2025-06-24 | John Tsai | Director | A | +3,902 | +$499.92K |
| 2025-06-24 | Daniella Beckman | Director | A | +3,902 | +$499.92K |
| 2025-06-05 | Percy H. Carter | CHIEF SCIENTIFIC OFFICER | Sell | −2,659 | −$340.03K |
| 2025-05-29 | Jeffrey W. Albers | Director | MIXED | — | −$325.44K |
| 2025-05-21 | Christina Rossi | CHIEF OPERATING OFFICER | Sell | −2,274 | −$228.56K |
| 2025-05-07 | Ariel Hurley | PRINCIPAL ACCOUNTING OFFICER | MIXED | — | −$134.85K |
| 2025-05-07 | Christina Rossi | CHIEF OPERATING OFFICER | Sell | −2,274 | −$231.39K |
| 2025-04-03 | Kate Haviland | CHIEF EXECUTIVE OFFICER | Sell | −2,498 | −$216.46K |
| 2025-03-26 | Christina Rossi | CHIEF OPERATING OFFICER | Sell | −2,274 | −$216.08K |
| 2025-03-17 | Jeffrey W. Albers | Director | Sell | −5,766 | −$512.02K |
| 2025-03-14 | Jeffrey W. Albers | Director | MIXED | — | −$388.12K |
| 2025-03-07 | Tracey L McCain | EVP AND CHIEF LEGAL OFFICER | Sell | −5,262 | −$467.27K |
| 2025-03-07 | Percy H. Carter | CHIEF SCIENTIFIC OFFICER | Sell | −3,530 | −$313.46K |
| 2025-03-07 | Christina Rossi | CHIEF OPERATING OFFICER | Sell | −6,495 | −$576.76K |
| 2025-03-07 | Ariel Hurley | PRINCIPAL ACCOUNTING OFFICER | Sell | −1,326 | −$117.75K |
| 2025-03-07 | Philina Lee | CHIEF COMMERCIAL OFFICER | Sell | −3,733 | −$331.49K |
| 2025-03-07 | Michael Landsittel | CHIEF FINANCIAL OFFICER | Sell | −5,284 | −$469.22K |
| 2025-03-07 | Fouad Namouni | PRESIDENT, R & D | Sell | −6,489 | −$576.22K |
| 2025-03-07 | Kate Haviland | CHIEF EXECUTIVE OFFICER | Sell | −16,151 | −$1.43M |
| 2025-03-07 | L. Becker Hewes | CHIEF MEDICAL OFFICER | Sell | −10,095 | −$890.64K |
| 2025-03-07 | Debra Durso-Bumpus | CHIEF PEOPLE OFFICER | Sell | −5,157 | −$457.94K |
| 2025-03-04 | Debra Durso-Bumpus | CHIEF PEOPLE OFFICER | A | +11,000 | — |
| 2025-03-04 | Christina Rossi | CHIEF OPERATING OFFICER | A | +13,200 | — |
| 2025-03-04 | Percy H. Carter | CHIEF SCIENTIFIC OFFICER | A | +11,000 | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Michael Landsittel | Chief Financial Officer | 94,277 | $12.21M |
| Tracey L McCain | EVP & Chief Legal Officer | 88,195 | $11.42M |
| Percy H. Carter | Chief Scientific Officer | 74,508 | $9.65M |
| Alexis Borisy | Director | 74,160 | $9.60M |
| Debra Durso-Bumpus | Chief People Officer | 70,959 | $9.19M |
| Christina Rossi | Chief Operating Officer | 20,628 | $2.67M |
| Lynn Seely | Director | 13,254 | $1.72M |
| Daniella Beckman | Director | 10,842 | $1.40M |
| Habib J Dable | Director | 8,742 | $1.13M |
| John Tsai | Director | 8,742 | $1.13M |
| L. Becker Hewes | Chief Medical Officer | 1,607 | $208.04K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the BPMC quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.